Tvardi Therapeutics (TVRD) Q4 2024 earnings summary

Executive summary

• Cara Therapeutics discontinued its clinical program in notalgia paresthetica (NP) after oral difelikefalin failed to show clinical benefit, leading to a 70% workforce reduction and a strategic shift to explore alternatives, including a merger with Tvardi Therapeutics and an asset sale to CSL Vifor.

• The company entered into a merger agreement with Tvardi Therapeutics, with Cara shareholders expected to own 15.25% of the combined company, and an asset sale agreement with CSL Vifor for $900,000, both contingent on shareholder and regulatory approvals.

• Cara's commercial product, KORSUVA injection, saw a sharp decline in U.S. net sales to $2.1 million in 2024, with negative net sales in some quarters due to price decreases and the expiration of favorable CMS reimbursement, resulting in minimal expected future revenue from this product.

• The company recorded a net loss of $70.9 million in 2024, with an accumulated deficit of $755.6 million as of year-end, and expects to continue incurring losses until a successful strategic transaction or new product development.

• Cara's future operations are highly dependent on the successful completion of the merger and asset disposition; failure could result in dissolution and liquidation.

Financial highlights

• Total revenue for 2024 was $7.1 million, down 66% from $21.0 million in 2023 and $41.9 million in 2022, driven by declines in collaborative and commercial supply revenue.

• Collaborative revenue fell 84% year-over-year to $2.1 million, primarily due to negative profit share from KORSUVA injection sales.

• Commercial supply revenue dropped 89% to $0.6 million in 2024.

• No license, milestone, or royalty revenue was recognized in 2024 due to the sale of future royalties and milestones to HCR.

• Net loss for 2024 was $70.9 million, compared to $118.5 million in 2023 and $85.5 million in 2022.

• Cash and cash equivalents at year-end 2024 were $37.9 million, with negative stockholders' equity of $4.6 million.

Outlook and guidance

• Cara expects no meaningful revenue from KORSUVA injection or related royalties/milestones in the foreseeable future.

• Current cash resources are expected to fund operations for at least the next 12 months, assuming no resumption of development activities.

• The company’s future is contingent on the successful completion of the merger with Tvardi and the asset sale to CSL Vifor; otherwise, dissolution is possible.